Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Does tumour dormancy offer a therapeutic target?

Author information

Affiliations

  • 1. Harvard Medical School, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Lawrence House, RH-302, Boston, Massachusetts 02114, USA.
      Authors
    • Goss PE 1
    (1 author)

ORCIDs linked to this article

Nature reviews. Cancer, 04 Nov 2010, 10(12):871-877
https://doi.org/10.1038/nrc2933 PMID: 21048784 

Review

Abstract 

The increasing number of cancer survivors is cause for celebration, but this expanding population has highlighted the problem of tumour dormancy, which can lead to relapse. As we start to understand more about the biology of dormant cancer cells, we can begin to address how best to treat this form of disease. Preclinical models and initial clinical trials, as exemplified in patients with breast cancer, are paving the way to address how best to treat long-term cancer survivors to minimize the risk of cancer recurrence.

Full text links 

Read article at publisher's site: https://doi.org/10.1038/nrc2933

References 

Articles referenced by this article (72)

Show 10 more references (10 of 72)

Citations & impact 

Impact metrics

194
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/41116910
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/41116910

Article citations

Go to all (194) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.